Physician profile
Peter A Tarbox
NPI 1063472678
$33,357.78
in general payments reported to CMS, 2019-2025
78 companies · $5,101 in 2025
The $5,101 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,414 · 2020: $3,904 · 2021: $4,629 · 2022: $4,850 · 2023: $5,787 · 2024: $5,673 · 2025: $5,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,527.25 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,539.89 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $2,253.68 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $2,021.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurelis, INC. | $1,901.37 | 2021-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $1,897.76 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,575.11 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,383.06 | 2019-2025 | Nuplazid |
| Celgene Corporation | $1,266.58 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $1,052.95 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $893.78 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $874.33 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Eisai INC. | $855.56 | 2020-2025 | |
| Emd Serono, INC. | $851.58 | 2019-2024 | |
| Lundbeck LLC | $799.73 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $710.53 | 2019-2025 | Uplizna, Aimovig |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Tarbox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.